Scholarlink

Background <p>Patients with chronic kidney disease have a high risk of fracture, but evidence-based treatment protocols for osteoporosis are lacking. Bisphosphonates are commonly used anti-resorptive drugs, but due to renal excretion, patients with chronic kidney disease have not been included in clinical trials.</p> Case presentation <p>We present a case of severe bone fragility in a patient on long-term hemodialysis therapy where zoledronate was well-tolerated and provided clinical improvement.</p> Conclusion <p>This case highlights the potential role of bisphosphonates in chronic kidney disease–associated osteoporosis and the need for trials to establish the safety and efficacy of anti-resorptive drugs in this patient population.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Zoledronic acid for chronic kidney disease–associated osteoporosis

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年2月25日

查看全文
  • Sukanya Sakthivel,
  • Krista Dybtved Kjærgaard,
  • Per Ivarsen,
  • Bente Langdahl,
  • Hanne Skou Jørgensen

摘要

Background

Patients with chronic kidney disease have a high risk of fracture, but evidence-based treatment protocols for osteoporosis are lacking. Bisphosphonates are commonly used anti-resorptive drugs, but due to renal excretion, patients with chronic kidney disease have not been included in clinical trials.

Case presentation

We present a case of severe bone fragility in a patient on long-term hemodialysis therapy where zoledronate was well-tolerated and provided clinical improvement.

Conclusion

This case highlights the potential role of bisphosphonates in chronic kidney disease–associated osteoporosis and the need for trials to establish the safety and efficacy of anti-resorptive drugs in this patient population.